Grifols, S.A. (GRFS)
NASDAQ: GRFS · Real-Time Price · USD
8.00
+0.01 (0.13%)
At close: Aug 21, 2026, 4:00 PM EDT
7.99
-0.01 (-0.12%)
After-hours: Aug 21, 2026, 4:16 PM EDT
Grifols Revenue
Grifols had revenue of 1.87B EUR in the quarter ending June 30, 2026, a decrease of -0.91%. This brings the company's revenue in the last twelve months to 7.42B, down -0.33% year-over-year. In the year 2025, Grifols had annual revenue of 7.52B with 4.33% growth.
Revenue (ttm)
7.42B EUR
Revenue Growth
-0.33%
P/S Ratio
0.82
Revenue / Employee
293,946 EUR
Employees
25,247
Market Cap
6.97B USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.52B | 312.00M | 4.33% |
| Dec 31, 2024 | 7.21B | 620.00M | 9.41% |
| Dec 31, 2023 | 6.59B | 528.03M | 8.71% |
| Dec 31, 2022 | 6.06B | 1.13B | 22.92% |
| Dec 31, 2021 | 4.93B | -406.92M | -7.62% |
| Dec 31, 2020 | 5.34B | 241.35M | 4.73% |
| Dec 31, 2019 | 5.10B | 611.97M | 13.64% |
| Dec 31, 2018 | 4.49B | 168.65M | 3.91% |
| Dec 31, 2017 | 4.32B | 268.24M | 6.62% |
| Dec 31, 2016 | 4.05B | 115.27M | 2.93% |
| Dec 31, 2015 | 3.93B | 579.18M | 17.26% |
| Dec 31, 2014 | 3.36B | 613.65M | 22.38% |
| Dec 31, 2013 | 2.74B | 120.79M | 4.61% |
| Dec 31, 2012 | 2.62B | 825.33M | 45.96% |
| Dec 31, 2011 | 1.80B | 804.88M | 81.24% |
| Dec 31, 2010 | 990.73M | 77.54M | 8.49% |
| Dec 31, 2009 | 913.19M | 98.88M | 12.14% |
| Dec 31, 2008 | 814.31M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Pfizer | 63.70B |
| AstraZeneca | 61.37B |
| Sanofi | 55.89B |
| Novo Nordisk | 50.34B |
| Bristol-Myers Squibb Company | 49.19B |
| GSK plc | 44.05B |
| Amgen | 38.10B |
| Gilead Sciences | 30.46B |
GRFS News
- 12 days ago - Grifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin Deficiency - GlobeNewsWire
- 25 days ago - Grifols Q2 Earnings Call Highlights - MarketBeat
- 25 days ago - Grifols Earnings Call Transcript: Q2 2026 - Transcripts
- 25 days ago - Grifols Quarterly report: Q2 2026 - Filings
- 25 days ago - Grifols Earnings release: Q2 2026 - Filings
- 25 days ago - Grifols Slides: Q2 2026 - Filings
- 5 weeks ago - Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins - GlobeNewsWire
- 2 months ago - Grifols Launches FESILTY™ (fibrinogen, human-chmt) in the U.S. - GlobeNewsWire